Clinical Trials Browser

Phase 4 × Lymphoma, B-Cell × Clear all

NCT07270835 2025-12-08

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

Phase 4 Recruiting

LymphoidMyeloid

Lymphoma, B-Cell, Lymphohistiocytosis, Hemophagocytic

NCT03229200 2025-10-30

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Phase 4 Active not recruiting

LymphoidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

NCT06956092 2025-05-02

Glofitamab

Phase 4 Not yet recruiting

Lymphoma, B-Cell

NCT05806580 2024-10-23

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

Phase 4 Recruiting

Recurrence, Lymphoma, B-Cell

NCT06609304 2024-10-15

axi-cel

Phase 4 Recruiting

Lymphoma, B-Cell

NCT05814848 2023-06-15

A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

Phase 4 Not yet recruiting

Recurrence, Lymphoma, B-Cell

NCT01990534 2021-04-09

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Phase 4 Completed

60 enrolled 21 charts

Hematologic Diseases, Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04152577 2019-11-05

R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL

Phase 4 Unknown

Lymphoma, B-Cell

NCT02992834 2016-12-14

Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma

Phase 4 Unknown

Lymphoma, B-Cell